STOCK TITAN

Tiziana Life Sciences (TLSA) COO discloses Form 3 share and option holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Tiziana Life Sciences Ltd executive Keeren Rameshchandra Shah, the Chief Operating & Financial Officer, filed an initial Form 3 reporting his beneficial ownership in the company. He holds 2,500 shares of common stock directly, along with multiple option awards over common shares.

These options cover various blocks of common stock at exercise prices of $0.50, $0.57, $0.82, $0.88 and $1.58 per share, with expiration dates ranging from 2030 to 2035. The filing lists these positions as existing holdings rather than new purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Shah Keeren Rameshchandra
Role CHIEF OPERATING & FIN. OFFICER
Type Security Shares Price Value
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding Options -- -- --
holding COMMON STOCK -- -- --
Holdings After Transaction: Options — 15,625 shares (Direct, null); COMMON STOCK — 2,500 shares (Direct, null)
Footnotes (1)
Direct common stock holding 2,500 shares Total shares of common stock held directly after reporting
Option grant exercise price $1.58 per share Options over 12,500 underlying common shares expiring 2035-09-04
Option grant exercise price $0.82 per share Options over 125,000 underlying common shares expiring 2034-10-03
Option grant exercise price $0.50 per share Options over 83,334 underlying common shares expiring 2034-03-13
Option grant exercise price $0.57 per share Options over 46,875 underlying common shares expiring 2033-03-14
Option grant exercise price $0.88 per share Options over 15,625 underlying common shares expiring 2030-05-06
Options financial
"Security title is "Options" with underlying common stock"
Options are contracts that give investors the right to buy or sell an asset at a specific price within a certain time frame. They function like a reservation or a ticket that allows for potential profit or protection against price changes, making them useful tools for managing investment risks or speculating on market movements.
exercise price financial
"Each option line includes an exercise price such as 0.5000 or 1.5800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"Option records list an expiration date running from 2030-05-06 to 2035-09-04"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"The underlying security title is reported as common stock for each option"
common stock financial
"Holdings include 2,500 shares of common stock held directly"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Shah Keeren Rameshchandra

(Last)(First)(Middle)
C/O TIZIANA LIFE SCIENCES LTD
14-15 CONDUIT STREET

(Street)
LONDONW1S 2XJ

(City)(State)(Zip)

UNITED KINGDOM

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
Tiziana Life Sciences Ltd [ TLSA ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF OPERATING & FIN. OFFICER
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
COMMON STOCK2,500D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Options05/06/202105/06/2030common stock15,625$0.88D
Options05/06/202205/06/2030common stock15,625$0.88D
Options05/06/202305/06/2030common stock15,625$0.88D
Options05/06/202405/06/2030common stock15,625$0.88D
Options03/14/202403/14/2033common stock46,875$0.57D
Options03/14/202503/14/2033common stock46,875$0.57D
Options03/14/202603/14/2033common stock46,875$0.57D
Options03/14/202703/14/2033common stock46,875$0.57D
Options03/13/202503/13/2034common stock83,333$0.5D
Options03/13/202603/13/2034common stock83,334$0.5D
Options03/13/202703/13/2034common stock83,333$0.5D
Options08/03/202610/03/2034common stock125,000$0.82D
Options08/03/202710/03/2034common stock125,000$0.82D
Options08/03/202810/03/2034common stock125,000$0.82D
Options04/03/202610/03/2034common stock125,000$0.82D
Options09/04/202609/04/2035common stock12,500$1.58D
Options09/04/202709/04/2035common stock12,500$1.58D
Options09/04/202809/04/2035common stock12,500$1.58D
Options09/04/202909/04/2035common stock12,500$1.58D
Explanation of Responses:
/s/ Keeren Shah05/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Tiziana Life Sciences (TLSA) Form 3 filing show for Keeren Shah?

The Form 3 shows that executive Keeren Rameshchandra Shah beneficially owns 2,500 TLSA common shares and multiple option grants. These options provide rights to buy common stock at fixed prices between $0.50 and $1.58 per share, expiring from 2030 through 2035.

How many Tiziana Life Sciences (TLSA) common shares does Keeren Shah hold directly?

Keeren Shah holds 2,500 shares of TLSA common stock directly. This equity stake is disclosed as part of his initial beneficial ownership statement, giving investors visibility into his direct share position separate from his stock option awards.

What stock option grants are reported for Keeren Shah in the TLSA Form 3?

The Form 3 lists several option positions over TLSA common stock with exercise prices of $0.50, $0.57, $0.82, $0.88 and $1.58. Each grant has a specified expiration date between 2030 and 2035, indicating long-dated incentives tied to the company’s share price.

Are there any buy or sell transactions in the Tiziana Life Sciences (TLSA) Form 3?

The filing presents Shah’s holdings as of the reporting date and does not show explicit buy or sell transactions. Entries are categorized as holdings, meaning the document primarily establishes his existing ownership in TLSA shares and options rather than recent trades.

What are the expiration dates for Keeren Shah’s TLSA stock options?

Shah’s reported TLSA stock options have expiration dates ranging from 2030-05-06 to 2035-09-04. These long-term expirations indicate multi-year incentive arrangements, allowing potential future exercises if Tiziana Life Sciences’ share price exceeds the respective exercise prices.